




Steven Witte

IABS Board Member
USA

In this role, he and his team directly support and accelerate technology transfers of veterinary biological products, such as vaccines, diagnostics, and biotherapeutics, to commercial manufacturers and other partners. At NBAF, he is responsible for planning, coordinating, and directing BDM operations with emphasis on strategic direction. He is also tasked to provide leadership for the development, production, and testing of vaccines and biologicals for use in animals.

Mr. Witte has worked in the biological development, research, and animal health fields for almost 30 years. Prior to joining NBAF, he was a senior research scientist team leader at Elanco in Indiana, where he managed the analytical and process development research team (PART) for food and companion animal vaccines and biotherapeutics.

Prior to his time at Elanco, Mr. Witte worked as a senior scientist for Pfizer Animal Health in Michigan and in Connecticut. In that role, he developed analytical tools and assays for vaccines for food and companion animals and was part of several teams that licensed such vaccines as CattleMaster Gold, BoviShield Gold and Inforce 3.



Steve earned a Master of Science degree in pathobiology from Kansas State University in 1999 and a Bachelor of Science degree in biology from the University of Kansas in 1994. While at KSU, Steve worked full-time at the College of Veterinary Medicine in the Department of Diagnostic Medicine/Pathobiology as a microbiologist in the Virus Serology lab.

As a virologist at Ghent University (1976-1980), Joris discovered H1N1 flu as a pathogen for swine leading to a better understanding of H1N1 as a zoonosis. After his assignment as Veterinary Officer to control animal diseases in Belgium and the EU, Joris joined Institut Mérieux animal health which became Rhône Mérieux and later on Merial, where he occupied leading positions in global vaccine development, strategy, regulatory affairs, marketing and production, for animal vaccines and flu vaccines.

In 2001 he joined The Vaccine Fund, where he coordinated relations with European institutions which led to substantial funding by the EU and European governments to GAVI. At Tuberculosis Vaccine Initiative (TBVI) in Lelystad, the Netherlands, Joris developed, with EU institutions, a financial and strategic framework about funding translation of innovation into vaccines for tuberculosis which would be accessible to global markets.

Joris is consultant for international organisations with particular emphasis on zoonoses, one Health approaches and health in developing countries.

